Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03094806 · ClinicalTrials.gov registry record · NA

Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD

A NA study of Chronic Obstructive Pulmonary Disease, sponsored by New York Presbyterian Brooklyn Methodist Hospital.

Completed
Registry status
NA
Development phase
91
Enrollment target
1
Study location

NCT03094806: Completed NA study of Chronic Obstructive Pulmonary Disease, sponsored by New York Presbyterian Brooklyn Methodist Hospital.

NCT03094806 is a NA study of Chronic Obstructive Pulmonary Disease that has completed, run by New York Presbyterian Brooklyn Methodist Hospital. The registered enrollment target is 91 participants, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03094806, a NA study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by New York Presbyterian Brooklyn Methodist Hospital.

COMPLETED
Registry status
NA
Development phase
91 participants
Enrollment target
1
Study location

Study Summary

This study is evaluating the use of a respiratory device, the Acapella Vibratory Positive Expiratory Pressure (PEP) Therapy device, in patients admitted to the hospital with a chronic obstructive pulmonary disease (COPD) exacerbation.

Primary Outcome

Time of admission to time of discharge from hospital

Interventions

  • DEVICE Acapella Vibratory PEP Therapy Device plus usual care
  • DEVICE Sham Acapella Vibratory PEP Device plus usual care

Study Locations (1)

New York

  • New York Methodist Hospital - Brooklyn

Trial Details

FieldValue
Enrollment Target 91 participants
Start Date 2013-10
Est. Completion 2015-12
Phase NA

What the finished NCT03094806 record still lists

NCT03094806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Acapella Vibratory PEP Therapy Device plus usual care is the first listed.

NCT03094806 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03094806 about?

NCT03094806 is a clinical study titled "Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD". This study is evaluating the use of a respiratory device, the Acapella Vibratory Positive Expiratory Pressure (PEP) Therapy device, in patients admitted to the hospital with a chronic obstructive pulmonary disease (COPD) exacerbation.

What is the current status of trial NCT03094806?

This trial is currently completed. It is a NA study. The enrollment target is 91 participants. The study started on 2013-10. Estimated completion is 2015-12.

What conditions does trial NCT03094806 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.

What interventions are being tested in trial NCT03094806?

The interventions under investigation include: Acapella Vibratory PEP Therapy Device plus usual care (DEVICE), Sham Acapella Vibratory PEP Device plus usual care (DEVICE).

Who is sponsoring clinical trial NCT03094806?

This trial is sponsored by New York Presbyterian Brooklyn Methodist Hospital, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03094806 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Obstructive Pulmonary Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03094806's enrollment target sits among peer trials

91 54th of 86 higher than 33 of 86 other Chronic Obstructive Pulmonary Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02671448 · 91 participants · NA

    Pilot Trial of Homebound Stem Cell Transplantation

  • NCT04835857 · 91 participants

    Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices

  • NCT05184842 · 91 participants · Phase 2

    Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

  • NCT05685173 · 91 participants · Phase 1

    A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03094806, the US trial registry maintained by the National Library of Medicine. NCT03094806 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.